Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease

20 septembre 2026 mis à jour par: Fatima Yaman, Kutahya Health Sciences University

Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease

This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.

Aperçu de l'étude

Statut

Pas encore de recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

46

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Kütahya, Turquie (Türkiye), 43020
        • Kutahya Health Sciences University
        • Contact:
        • Chercheur principal:
          • Fatima YAMAN, Assoc. Prof
        • Chercheur principal:
          • Meltem ÇOBAN, Dr.
        • Sous-enquêteur:
          • Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
        • Sous-enquêteur:
          • Mevlüt DEMİR, Assoc. Prof
        • Sous-enquêteur:
          • Cansu OZBAYER, Prof. Dr.
        • Sous-enquêteur:
          • Fatih KAR, Assoc. Prof.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

35 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Stable coronary artery disease
  • History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Referred and considered clinically eligible for a structured cardiac rehabilitation program
  • Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
  • Ability and willingness to participate in the study and complete the cardiac rehabilitation program

Exclusion Criteria:

  • Symptoms or signs of myocardial ischemia
  • Significant left ventricular outflow tract obstruction
  • Ventricular arrhythmia
  • Significant valvular heart disease
  • Uncontrolled hypertension
  • Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
  • Active malignancy
  • Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
  • Body mass index greater than 35 kg/m²
  • History of orthopedic surgery within the previous 6 months
  • Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
  • Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
  • Known psychiatric disorder
  • Presence of a permanent cardiac pacemaker

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Personalized Cardiac Rehabilitation Group

Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program.

Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in miRNA Expression Levels
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Peak Oxygen Uptake (VO₂max)
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Exercise Workload
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Six-Minute Walk Test Distance
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Resting Heart Rate
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Heart Rate
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Health-Related Quality of Life
Délai: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 septembre 2026

Achèvement primaire (Estimé)

31 décembre 2026

Achèvement de l'étude (Estimé)

1 février 2027

Dates d'inscription aux études

Première soumission

20 septembre 2026

Première soumission répondant aux critères de contrôle qualité

20 septembre 2026

Première publication (Réel)

25 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner